Science News
from research organizations

Marker of Ewing sarcoma: Potential new drug target?

Date:
February 22, 2010
Source:
Journal of Clinical Investigation
Summary:
Ewing sarcoma (EWS) is a bone tumor that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown. Now, researchers have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS.
Share:
       
FULL STORY

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown.

Now, Katia Scotlandi and colleagues, at SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy, have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS.

In the study, decreasing CD99 expression in human EWS cell lines reduced their ability to form tumors xenografted into mice. In vitro, it increased expression of H-neurofilament, a marker of neuronal differentiation. Consistent with this, an inverse correlation between CD99 expression and H-neurofilament expression, neural differentiation, and oncogenic transformation was observed in patient-derived EWS cells.

The authors therefore conclude that CD99 prevents neural differentiation and suggest that blocking it might provide a new approach to treating EWS.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Anna Rocchi, Maria Cristina Manara, Marika Sciandra, Diana Zambelli, Filippo Nardi, Giordano Nicoletti, Cecilia Garofalo, Stefania Meschini, Annalisa Astolfi, Mario P. Colombo, Stephen L. Lessnick, Piero Picci and Katia Scotlandi. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI36667

Cite This Page:

Journal of Clinical Investigation. "Marker of Ewing sarcoma: Potential new drug target?." ScienceDaily. ScienceDaily, 22 February 2010. <www.sciencedaily.com/releases/2010/02/100208185204.htm>.
Journal of Clinical Investigation. (2010, February 22). Marker of Ewing sarcoma: Potential new drug target?. ScienceDaily. Retrieved August 4, 2015 from www.sciencedaily.com/releases/2010/02/100208185204.htm
Journal of Clinical Investigation. "Marker of Ewing sarcoma: Potential new drug target?." ScienceDaily. www.sciencedaily.com/releases/2010/02/100208185204.htm (accessed August 4, 2015).

Share This Page: